These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 31666715)

  • 1. Context-dependent roles of complement in cancer.
    Roumenina LT; Daugan MV; Petitprez F; Sautès-Fridman C; Fridman WH
    Nat Rev Cancer; 2019 Dec; 19(12):698-715. PubMed ID: 31666715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complement system as a target in cancer immunotherapy.
    Merle NS; Roumenina LT
    Eur J Immunol; 2024 Oct; 54(10):e2350820. PubMed ID: 38996361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement as a Biological Tool to Control Tumor Growth.
    Macor P; Capolla S; Tedesco F
    Front Immunol; 2018; 9():2203. PubMed ID: 30319647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
    Gilabert-Oriol R; Ryan GM; Leung AWY; Firmino NS; Bennewith KL; Bally MB
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of complement in tumor growth.
    Pio R; Corrales L; Lambris JD
    Adv Exp Med Biol; 2014; 772():229-62. PubMed ID: 24272362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical role of the TME in solid cancer.
    Giraldo NA; Sanchez-Salas R; Peske JD; Vano Y; Becht E; Petitprez F; Validire P; Ingels A; Cathelineau X; Fridman WH; Sautès-Fridman C
    Br J Cancer; 2019 Jan; 120(1):45-53. PubMed ID: 30413828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement in monoclonal antibody therapy of cancer.
    Rogers LM; Veeramani S; Weiner GJ
    Immunol Res; 2014 Aug; 59(1-3):203-10. PubMed ID: 24906530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumour microenvironment links complement system dysregulation and hypoxic signalling.
    Olcina MM; Kim RK; Melemenidis S; Graves EE; Giaccia AJ
    Br J Radiol; 2019 Jan; 92(1093):20180069. PubMed ID: 29544344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement inhibition in cancer therapy.
    Pio R; Ajona D; Lambris JD
    Semin Immunol; 2013 Feb; 25(1):54-64. PubMed ID: 23706991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and the complement cascade.
    Rutkowski MJ; Sughrue ME; Kane AJ; Mills SA; Parsa AT
    Mol Cancer Res; 2010 Nov; 8(11):1453-65. PubMed ID: 20870736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement in cancer: untangling an intricate relationship.
    Reis ES; Mastellos DC; Ricklin D; Mantovani A; Lambris JD
    Nat Rev Immunol; 2018 Jan; 18(1):5-18. PubMed ID: 28920587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
    Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
    Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Yin Yang of Complement and Cancer.
    Meri S; Magrini E; Mantovani A; Garlanda C
    Cancer Immunol Res; 2023 Dec; 11(12):1578-1588. PubMed ID: 37902610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarities between Tumour Immune Response and Chronic Wound Microenvironment: Influence of Mesenchymal Stromal/Stem Cells.
    Peta KT; Ambele MA; Pepper MS
    J Immunol Res; 2021; 2021():6649314. PubMed ID: 33860061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the gut microbiota on immune cell interactions and cancer treatment.
    Liu C; Fu L; Wang Y; Yang W
    J Transl Med; 2024 Oct; 22(1):939. PubMed ID: 39407240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer.
    Zheng M; Li YM; Liu ZY; Zhang X; Zhou Y; Jiang JL; Zhu P; Yang XM; Tang J; Chen ZN
    Front Immunol; 2021; 12():731329. PubMed ID: 35069521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual role of complement in cancers, from destroying tumors to promoting tumor development.
    Lu P; Ma Y; Wei S; Liang X
    Cytokine; 2021 Jul; 143():155522. PubMed ID: 33849765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
    Zhang L; Sorensen MD; Kristensen BW; Reifenberger G; McIntyre TM; Lin F
    Clin Cancer Res; 2018 Nov; 24(21):5381-5391. PubMed ID: 30006485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.